National Institutes of Health’s Long COVID Initiative To Assess Pfizer’s Antiviral Pill As Potential Treatment
The National Institutes of Health's $1 billion RECOVER Initiative has decided to study Pfizer Inc's (NYSE: PFE) antiviral drug Paxlovid as a potential treatment for long COVID.